{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:58:56Z","timestamp":1789725536643,"version":"4.0.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.critrevonc.2015.02.012","type":"journal-article","created":{"date-parts":[[2015,3,6]],"date-time":"2015-03-06T10:41:45Z","timestamp":1425638505000},"page":"279-290","source":"Crossref","is-referenced-by-count":20,"title":["Trabectedin: Supportive care strategies and safety profile"],"prefix":"10.1016","volume":"94","author":[{"given":"Karin","family":"Jordan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Jahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berit","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"M\u00fcller-Tidow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rn","family":"R\u00fcssel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2015.02.012_bib0250","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1470-2045(07)70181-X","article-title":"Trabectedin \u2013 a targeted chemotherapy","volume":"8","author":"von Mehren","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.critrevonc.2015.02.012_bib0255","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1158\/1535-7163.MCT-10-0263","article-title":"A review of trabectedin (ET-743): a unique mechanism of action","volume":"9","author":"D\u2019Incalci","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.critrevonc.2015.02.012_bib0260","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.phrs.2004.12.001","article-title":"Hepatotoxicity and metabolism of trabectedin: a literature review","volume":"51","author":"Beumer","year":"2005","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.critrevonc.2015.02.012_bib0265","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s40259-014-0100-7","article-title":"A comprehensive safety evaluation of trabectedin and drug\u2013drug interactions of trabectedin-based combinations","volume":"28","author":"Leporini","year":"2014","journal-title":"BioDrugs: Clin immunotherapeut Biopharmaceut Gene Therapy"},{"key":"10.1016\/j.critrevonc.2015.02.012_bib0270","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s00280-011-1718-5","article-title":"Pharmacokinetics of trabectedin on hemodialysis: an application for the management of cancer patients with end-stage renal disease","volume":"68","author":"Thariat","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.critrevonc.2015.02.012_bib0275","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1200\/JCO.2009.25.4037","article-title":"Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer","volume":"28","author":"Monk","year":"2010","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2015.02.012_bib0280","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1200\/JCO.2008.21.0088","article-title":"Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules","volume":"27","author":"Demetri","year":"2009","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2015.02.012_bib0285","first-page":"10563","article-title":"A large retrospective analysis of trabectedin in 885 patients with advanced soft tissue sarcoma","volume":"31","author":"Le Cesne","year":"2013","journal-title":"ASCO Meeting Abst"},{"key":"10.1016\/j.critrevonc.2015.02.012_bib0290","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/cncr.11563","article-title":"Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma","volume":"98","author":"Laverdiere","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2015.02.012_bib0295","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1200\/JCO.2005.01.180","article-title":"Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial","volume":"23","author":"Le Cesne","year":"2005","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2015.02.012_bib0300","doi-asserted-by":"crossref","first-page":"5484","DOI":"10.1200\/JCO.2005.05.028","article-title":"Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study","volume":"23","author":"Garcia-Carbonero","year":"2005","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2015.02.012_bib0305","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1200\/JCO.2004.02.098","article-title":"Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy","volume":"22","author":"Garcia-Carbonero","year":"2004","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2015.02.012_bib0310","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.2004.05.210","article-title":"Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients","volume":"22","author":"Yovine","year":"2004","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2015.02.012_bib0315","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1093\/annonc\/mdn363","article-title":"A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies","volume":"19","author":"von Mehren","year":"2008","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.critrevonc.2015.02.012_bib0320","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s10637-010-9561-9","article-title":"Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone","volume":"30","author":"Paz-Ares","year":"2012","journal-title":"Investig New Drugs"},{"key":"10.1016\/j.critrevonc.2015.02.012_bib0325","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00280-007-0583-8","article-title":"Semimechanistic pharmacokinetic\/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment","volume":"62","author":"Fetterly","year":"2008","journal-title":"Cancer Chemotherapy Pharmacol"},{"key":"10.1016\/j.critrevonc.2015.02.012_bib0330","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.ejca.2006.02.010","article-title":"Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma","volume":"42","author":"Grosso","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.critrevonc.2015.02.012_bib0335","series-title":"Yondelis\u00ae \u2013 Product information","author":"European Medicines Agency (EMA)","year":"2013"},{"key":"10.1016\/j.critrevonc.2015.02.012_bib0340","series-title":"Trabectedin, (Yondelis), package leaflet","author":"Pharma Mar","year":"2012"},{"key":"10.1016\/j.critrevonc.2015.02.012_bib0345","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/sj.clpt.6100259","article-title":"Mechanism-based pharmacokinetic\/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia","volume":"83","author":"Hing","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.critrevonc.2015.02.012_bib0350","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1038\/bjc.2013.524","article-title":"Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials","volume":"109","author":"Le Cesne","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.critrevonc.2015.02.012_bib0355","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1093\/annonc\/mdu035","volume":"25","author":"Vehreschild","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2015.02.012_bib0360","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","article-title":"2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline","volume":"24","author":"Smith","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2015.02.012_bib0365","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","article-title":"2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours","volume":"47","author":"Aapro","year":"2011","journal-title":"Eur J Cancer"},{"issue":"Suppl. 5","key":"10.1016\/j.critrevonc.2015.02.012_bib0370","doi-asserted-by":"crossref","first-page":"v232","DOI":"10.1093\/annonc\/mdq194","article-title":"Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference","volume":"21","author":"Roila","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2015.02.012_bib0375","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1200\/JCO.2010.34.4614","article-title":"Antiemetics: American Society of Clinical Oncology clinical practice guideline update","volume":"29","author":"Basch","year":"2011","journal-title":"J Clin Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.critrevonc.2015.02.012_bib0380","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1007\/s00520-010-0985-8","article-title":"Guidelines for the control of nausea and vomiting with chemotherapy of low or minimal emetic potential","volume":"19","author":"Olver","year":"2011","journal-title":"Support Care Cancer: Off J Multinatl Assoc Support Care Cancer"},{"key":"10.1016\/j.critrevonc.2015.02.012_bib0385","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/0091270003262950","article-title":"Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity","volume":"44","author":"Shadle","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.critrevonc.2015.02.012_bib0390","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000348524","article-title":"Management of cytotoxic extravasation \u2013 ASORS expert opinion for diagnosis, prevention and treatment","volume":"36","author":"de Wit","year":"2013","journal-title":"Onkologie"},{"issue":"Suppl. 7","key":"10.1016\/j.critrevonc.2015.02.012_bib0395","doi-asserted-by":"crossref","first-page":"vii167","DOI":"10.1093\/annonc\/mds294","article-title":"Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines","volume":"23","author":"Perez Fidalgo","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2015.02.012_bib0400","series-title":"Yondelis (INN-trabectidin): Annex 1. Summary of product characteristics","author":"European Medicines Agency","year":"2008"},{"key":"10.1016\/j.critrevonc.2015.02.012_bib0405","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1200\/JCO.2008.21.6473","article-title":"Recognition of a new chemotherapeutic vesicant: trabectedin (ecteinascidin-743) extravasation with skin and soft tissue damage","volume":"27","author":"Theman","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2015.02.012_bib0410","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s10637-011-9662-0","article-title":"A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials","volume":"30","author":"Le Cesne","year":"2012","journal-title":"Investig New Drugs"},{"key":"10.1016\/j.critrevonc.2015.02.012_bib0415","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1007\/s00280-012-1864-4","article-title":"A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin","volume":"69","author":"Grosso","year":"2012","journal-title":"Cancer Chemotherapy Pharmacol"},{"key":"10.1016\/j.critrevonc.2015.02.012_bib0420","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/jnci\/djt181","article-title":"Wisconsin Ginseng (Panax quinquefolius) to Improve Cancer-Related Fatigue: a randomized, double-blind trial N07C2","volume":"105","author":"Barton","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.critrevonc.2015.02.012_bib0425","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0009-739X(05)70881-2","article-title":"Surgical treatment of recurrent secondary hyperparathyroidism","volume":"78","author":"Jimeno","year":"2005","journal-title":"Cir Esp"},{"key":"10.1016\/j.critrevonc.2015.02.012_bib0430","first-page":"CD006145","article-title":"Exercise for the management of cancer-related fatigue in adults","volume":"11","author":"Cramp","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.critrevonc.2015.02.012_bib0435","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1200\/JCO.2012.44.4661","article-title":"Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized. placebo-controlled trial in patients with advanced cancer","volume":"25","author":"Yennurajalingam","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2015.02.012_bib0440","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.2217\/fon.14.10","article-title":"Trabectedin for advanced soft tissue sarcomas: a single institution experience","volume":"11","author":"Gounaris","year":"2014","journal-title":"Future Oncol"},{"key":"10.1016\/j.critrevonc.2015.02.012_bib0445","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s00280-011-1614-z","article-title":"Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis","volume":"68","author":"Lebedinsky","year":"2011","journal-title":"Cancer Chemotherapy Pharmacol"},{"key":"10.1016\/j.critrevonc.2015.02.012_bib0450","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00280-011-1697-6","article-title":"Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies","volume":"69","author":"Thertulien","year":"2012","journal-title":"Cancer Chemotherapy Pharmacol"},{"key":"10.1016\/j.critrevonc.2015.02.012_bib0455","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2217\/fon.13.163","article-title":"Efficacy and safety of trabectedin as an early treatment for advanced or metastatic liposarcoma and leiomyosarcoma","volume":"10","author":"Blay","year":"2014","journal-title":"Future Oncol"},{"key":"10.1016\/j.critrevonc.2015.02.012_bib0460","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1517\/14740338.2013.829037","article-title":"Safety evaluation of trabectedin in treatment of soft-tissue sarcomas","volume":"12","author":"Martin-Liberal","year":"2013","journal-title":"Expert Opin Drug Safety"},{"key":"10.1016\/j.critrevonc.2015.02.012_bib0465","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1093\/annonc\/mds659","article-title":"Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study","volume":"24","author":"Samuels","year":"2013","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.critrevonc.2015.02.012_bib0470","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1200\/JCO.2005.09.032","article-title":"Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails","volume":"23","author":"Sessa","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2015.02.012_bib0475","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1016\/j.ejca.2012.05.012","article-title":"A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas","volume":"48","author":"Le Cesne","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.critrevonc.2015.02.012_bib0480","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1038\/sj.bjc.6604088","article-title":"A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens","volume":"97","author":"Krasner","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.critrevonc.2015.02.012_bib0485","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S1470-2045(07)70175-4","article-title":"Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study","volume":"8","author":"Grosso","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.critrevonc.2015.02.012_bib0490","series-title":"Cancer related fatigue. NCCN guideline, 2013. V.1","author":"NCCN","year":"2013"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842815000451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842815000451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,30]],"date-time":"2020-08-30T15:39:39Z","timestamp":1598801979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842815000451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S1040842815000451"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2015.02.012","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]}}}